NCT00532519

Brief Summary

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders. We hypothesize that a group of these patients may benefit from antidepressant therapy.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 19, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 20, 2007

Completed
Last Updated

September 20, 2007

Status Verified

September 1, 2007

First QC Date

September 19, 2007

Last Update Submit

September 19, 2007

Conditions

Prurigo Nodularis

Interventions

citalopram (cipralex)DRUG

10-20 mg/day, for 12 weeks.

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

You may not qualify if:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

: Hadassah Medical Organization,

Jerusalem, Israel

Location

MeSH Terms

Interventions

CitalopramDexetimide

Intervention Hierarchy (Ancestors)

PropylaminesAminesOrganic ChemicalsNitrilesBenzofuransHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPiperidonesPiperidinesHeterocyclic Compounds, 1-Ring

Study Officials

  • liran horev, md

    Hadassah Medical Organization

    PRINCIPAL INVESTIGATOR

  • rena cooper-kazaz, md

    Hadassah Medical Organization

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Liran Horev, MD

CONTACT

OO97226777111LIRAN_CH@BEZEQINT.NET

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 19, 2007

First Posted

September 20, 2007

Last Updated

September 20, 2007

Record last verified: 2007-09

Locations

IL(1)